e-learning
resources
Munich 2006
Tuesday 05.09.2006
Hospital-acquired pneumonia: from inflammation to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values
E. Chacón, A. Tejada, J. Casalduero, F. Clau, T. Martín, F. de Pablo, S. Bello (Zaragoza, Spain)
Source:
Annual Congress 2006 - Hospital-acquired pneumonia: from inflammation to treatment
Session:
Hospital-acquired pneumonia: from inflammation to treatment
Session type:
Poster Discussion
Number:
4504
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Chacón, A. Tejada, J. Casalduero, F. Clau, T. Martín, F. de Pablo, S. Bello (Zaragoza, Spain). Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values. Eur Respir J 2006; 28: Suppl. 50, 4504
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Mortality in patients with ventilator-associated pneumonia (VAP) and severe sepsis is determined by the number of organ failures
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Ventilator-associated pneumonia (VAP): epidemiology, empirical treatment and outcome
Source: Eur Respir J 2005; 26: Suppl. 49, 188s
Year: 2005
Treatment failure of severe and ventilator-associated pneumonia
Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections
Year: 2012
Type of acute respiratory failure and development of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Predictive value of procalcitonin in ventilator-associated pneumonia
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
How to prevent ventilator-associated pneumonia
Source: Annual Congress 2013 –PG3 Infections and critical patients: emerging problems and clinical strategies
Year: 2013
Cost of treatment failure in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 195s
Year: 2007
Challenges in the management of hospital-acquired pneumonia including ventilator-associated pneumonia
Source: ERS Course 2018 - Respiratory Infections
Year: 2018
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Source: Eur Respir J 2009; 34: 1364-1375
Year: 2009
Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 357s
Year: 2002
Evidence on measures for the prevention of ventilator-associated pneumonia
Source: Eur Respir J 2007; 30: 1193-1207
Year: 2007
Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Biomarkers and severity in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
Validation of pneumonia severity models for healthcare-associated pneumonia (HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
MR-proANP and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003
Copeptin and prognosis of ventilator-associated pneumonia
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept